By Stephen Nakrosis
Shares of Humacyte fell in post-market trading after the company said it was selling additional shares of its common stock.
The biotechnology company's shares were down 20% to $2.31 following the close, putting them below the 52-week low of $2.75 set on March 13. The stock ended the market session down 13% at $2.87.
Proceeds from the offering are slated to fund the commercialization of Symvess in the vascular trauma indication, development of product candidates in the company's pipeline, and for working capital and general corporate purposes, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 25, 2025 18:15 ET (22:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.